Yvo Graus

USPTO Granted Patents = 18 (Patent Applications = 8)

CIPO Patents = 2

EPO Patents = 16 (Patent Applications = 11)

Average Co-Inventor Count = 9.6

ph-index = 9

Forward Citations = 351(Granted Patents)

Location History:

Ede, NL (2008 - 2009)
Odijk, NL (2009 - 2015)
Odjik, NL (2015)

Company Filing History:

9 out of 4,942

Hoffmann-la Roche Inc.

Years Active: 2008-2015

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9187565 - Antibodies against CD38 for treatment of multiple myeloma (2015-11-17),

2. 9181344 - Use of effector-function-deficient antibodies for treatment of auto-immune diseases (2015-11-10),

3. 9102733 - Anti-OX40L antibodies (2015-08-11),

4. 9040050 - Combination treatment of CD38-expressing tumors (2015-05-26),

5. RE44389 - Methods of inhibiting the binding of P-selectin to PSGL-1 with anti-P-selectin antibodies (2013-07-22),

6. RE44359 - Nucleic acid molecules encoding anti-P-selectin antibodies (2013-07-08),

7. RE43568 - Anti-P-selectin antibodies (2012-08-06),

8. 7868141 - Anti-OX40L antibodies (2011-01-11),

9. 7850962 - Human monoclonal antibodies against CD20 (2010-12-14),

10. 7829673 - Antibodies against CD38 for treatment of multiple myeloma (2010-11-09),

11. 7824684 - Methods of inhibiting the binding of P-selectin to PSGL-1 with anti-P-selectin antibodies (2010-11-02),

12. 7807158 - Antibodies against IL-13 receptor alpha1 and uses thereof (2010-10-05),

13. 7754867 - Nucleic acid molecules encoding anti-P-selectin antibodies (2010-07-13),

14. 7579157 - Antibody selection method against IGF-IR (2009-08-25),

15. 7572897 - Antibodies against insulin-like growth factor I receptor and uses thereof (2009-08-11),

Title: Yvo Graus: Innovator in Antibody Development

Introduction

Yvo Graus is a prominent inventor based in Odijk, Netherlands, known for his significant contributions to the field of antibody research. With a total of 18 patents to his name, he has made remarkable strides in developing therapeutic solutions for various diseases, particularly in the realm of oncology and autoimmune disorders.

Latest Patents

Among his latest patents, Graus has developed antibodies against CD38 for the treatment of multiple myeloma. This patent discloses isolated human monoclonal antibodies that bind to human CD38, along with related antibody-based compositions and molecules. Additionally, he has introduced pharmaceutical compositions comprising these human antibodies, as well as therapeutic and diagnostic methods for their use. Another notable invention involves the use of effector-function-deficient antibodies for the treatment of autoimmune diseases. This invention specifically addresses the treatment of disorders such as myasthenia gravis by administering antibodies that can compete with auto-antibodies for binding to target auto-antigens.

Career Highlights

Throughout his career, Yvo Graus has worked with leading companies in the pharmaceutical industry, including Hoffmann-La Roche Inc. and Genmab A/S. His work in these organizations has allowed him to further his research and development efforts in antibody therapies, contributing to advancements in medical treatments.

Collaborations

Graus has collaborated with notable professionals in the field, including Paul Parren and Jan Van De Winkel. These collaborations have enhanced his research and have been instrumental in the development of innovative therapeutic solutions.

Conclusion

Yvo Graus stands out as a key figure in the field of antibody research, with a strong portfolio of patents that reflect his dedication to improving treatment options for patients. His innovative work continues to influence the landscape of medical therapies, particularly in oncology and autoimmune diseases.

This text is generated by artificial intelligence and may not be accurate.